Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ResMed Inc. Common Stock
(NY:
RMD
)
229.94
-22.89 (-9.05%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ResMed Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
ResMed (NYSE:RMD) Delivers Quality Dividend Strength for Income Investors
↗
Today 7:00 EDT
Via
Chartmill
S&P 500 Unusual Volume Movers for Oct. 30, 2026
↗
October 30, 2026
Via
Chartmill
Topics
Stocks
RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscape
October 30, 2026
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1....
Via
StockStory
Topics
Economy
ResMed (RMD) Q1 2027 Earnings Call Transcript
↗
October 30, 2026
Sleep device revenue grew 6% as AI tools boost therapy compliance and partnerships expand.
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
ResMed (NYSE:RMD) Offers Dividend Investors a Sustainable Payout Built on Quality Fundamentals
↗
October 07, 2026
Via
Chartmill
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts
↗
September 03, 2026
Via
Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume.
↗
August 07, 2026
Via
Chartmill
ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9%
↗
August 06, 2026
Via
Chartmill
What ResMed (RMD) Said on Its Q1 Earnings Call
↗
October 30, 2026
ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks...
Via
MarketBeat
Topics
Earnings
ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026
October 29, 2026
Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q1 2027), with revenue rising 5.9% year on year t...
Via
StockStory
ResMed (RMD) Q3 earnings report preview: what to look for
October 27, 2026
Medical device company ResMed (NYSE:RMD) will be reporting results this Thursday after market hours. Here’s what you need to know. ResMed met analysts’ reven...
Via
StockStory
Topics
Artificial Intelligence
Wednesday's session: top gainers and losers in the S&P500 index
↗
October 07, 2026
Via
Chartmill
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings?
October 05, 2026
ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell short of...
Via
StockStory
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
October 02, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
↗
September 21, 2026
ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing...
Via
MarketBeat
Discover which S&P500 stocks are making waves on Tuesday.
↗
September 15, 2026
Via
Chartmill
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest
September 13, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers. Patient monit...
Via
StockStory
Topics
Artificial Intelligence
2 Profitable Stocks Worth Investigating and 1 We Turn Down
September 01, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore
August 27, 2026
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
Via
StockStory
Topics
Stocks
ResMed (RMD) Q4 2026 Earnings Call Transcript
↗
August 14, 2026
Farrell discusses strategic divestitures, capital returns, and AI digital health expansion.
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
August 13, 2026
ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management ...
Via
StockStory
Topics
Earnings
Economy
Which S&P500 stocks are moving before the opening bell on Wednesday?
↗
August 12, 2026
Via
Chartmill
ResMed Q4 Earnings Call Highlights
↗
August 09, 2026
ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share...
Via
MarketBeat
Topics
Earnings
Economy
Stay informed with the top movers within the S&P500 index on Friday.
↗
August 07, 2026
Via
Chartmill
Top S&P500 movers in Friday's session
↗
August 07, 2026
Via
Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
↗
August 07, 2026
Via
Chartmill
Which S&P500 stocks are moving before the opening bell on Friday?
↗
August 07, 2026
Via
Chartmill
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
August 07, 2026
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ...
Via
StockStory
Topics
Economy
ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
August 06, 2026
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ...
Via
StockStory
ResMed (RMD) Q2 Earnings: What To Expect
August 04, 2026
Medical device company ResMed (NYSE:RMD) will be announcing earnings results this Thursday after the bell. Here’s what to expect. ResMed beat analysts’ reven...
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.